Pfizer’s Seagen Acquisition Brings It Full Circle in a Hot Area of Cancer Drug R&D
Seagen, the biotech company Pfizer is buying for $43 billion, is considered a pioneer in the class of cancer drugs called antibody drug conjugates. But the first ADC to reach the market wasn’t a…
Continue Reading